The Delta variant: updates from the new @PHE_Uk report assets.publishing.service.gov.uk/government/upl…
1st dose vaccine (either AZ or Pfizer) quite protective vs hospitalization
Fully vaxxed vs unvaxxed:
Infections 7.7% vs 67%
Hospitalizations 8% vs 48%
Delta's secondary attack rate is coming down some in the latest dataset. Its enhanced transmission over alpha appears to be more in the 40-60% range
Reinfections by sequencing data: 311/1260 were Delta
This 71-page report is rich. And that 60% of infections are getting sequenced (91% are Delta) is quite impressive.
It makes the output from CDC and the genomic surveillance in the US particularly weak
Here is the latest @CDCgov variant report. It is from May 22 and it's frankly pathetic when you compare it to @PHE_UK, both with respect to it being out of date and the lack of sequencing in the US covid.cdc.gov/covid-data-tra…
Contrast today's @PHE_UK report from genome sequencing (60% of cases) up to 4 days ago -- >60,000 Delta cases with vaccination status and outcomes
New US Covid genomic surveillance
The KP.3.1.1 variant is on the move to become dominant, more of a challenge to our immune response than KP.3 and prior variants (especially without new KP.2 booster when we need it for high-risk individuals)
It's the deletion 31/31 that makes the KP.3.1.1 spike different, but otherwise 2 mutations away from KP.2 (R346T and Q493E)
Buckle up; this wave isn't over yet d/t KP.3.1.1's emergence
We've known about KP.3's marked growth advantage since April and could have made the call then to make the new booster. That would have been aligned well with the current wave (available in July) 2/5 erictopol.substack.com/p/are-we-flirt…
But the FDA has tried to force fit Covid into an annual shot like flu, even though all data tells us it doesn't follow an annual pattern. Even the CDC acknowledges this now
3/5cdc.gov/ncird/whats-ne…
New CDC genomic data shows continued rise of the KP.3 variant that accounts for 1 of 3 Covid cases.
LB.1 is gaining, too, as JN.1 fades away
This variant growth advantage plot by @BenjMurrell (H/T @siamosolocani) shows why this is the case. Note KP.3 is the one at far left w/ almost 3-fold advantage to JN.1.
Reinforces why the decision to develop the KP.2 vaccine booster (instead of JN.1) was a good one
Spike mutation map to show the differences betweem KP.3 and JN.1 (and LB.1, KP.2)
The connection between #SARSCoV2 and neurodegeneration
@TheLancetNeuro
Quotes below: 1. SARS-CoV-2 infection should be considered as a risk factor for Alzheimer’s disease, even though the distinction between causation versus disease acceleration is not clear.thelancet.com/journals/laneu…
2. Inflammation in patients with COVID-19, and controlled experiments show prolonged neuro-inflammation after mild SARS-CoV-2 infection
in macaques.
3. A direct correlation has been reported
between prior SARS-CoV-2 infection and increased risk
of Alzheimer’s disease (figure).
4. So far, the estimated lifetime cumulative risk of dementia due to hospitalisation for any viral infection is 1·48 (95% CI 1·15–1·91).
Breaking down the risks and benefit for lecanemab, the amyloid beta-directed antibody vs Alzheimer's drug approved @US_FDA last year. It doesn't look good.